Philips Genomics Workspace enables integration of the largest-scale FDA-cleared cancer genetic test at NYU Langone Health
August 03 2021 - 9:00AM
Philips Genomics Workspace enables integration of the largest-scale
FDA-cleared cancer genetic test at NYU Langone Health
August 3, 2021
- Philips and NYU Langone Health Department of Pathology, a
premier NCI (National Cancer Institute) designated comprehensive
cancer center, collaborate for genomic processing, interpretation
and reporting
- Leveraging Philips Genomics Workspace hosted on Philips
HealthSuite, NGS (Next-Generation Sequencing) is integrated
directly into NYU Langone’s EMR for seamless, secure data sharing
and integrated decision-making
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
announced that New York Langone Health’s Department of Pathology
will leverage Philips Genomics Workspace (formerly part of
IntelliSpace Precision Medicine Platform) to integrate into their
EMR (electronic medical record) environment. This will enable the
largest cancer sequencing test in the industry, helping to guide
more confident treatment decisions and care pathways for patients
who have received a cancer diagnosis.
Genetic test for all cancers designed by NYU Langone’s
molecular pathologistsCleared by the FDA (U.S. Food and
Drug Administration) earlier this month under its 510(k)
designation for clinical lab use, the NYU Langone Genome PACT
(Profiling of Actionable Cancer Targets) test detects changes in
the DNA code of 607 genes linked by past studies to the development
of multiple types of cancer. The number of genes cancer types
assayed is the largest among academic genomic sequencing tests of
its kind.
PACT uses next-generation sequencing (NGS) technology, which can
read the sequence of the molecular ‘letters’ making up DNA code
within hundreds of genes simultaneously, and covers the most genes
of any FDA-cleared NGS test to-date. The technology matches the
genetics of each patient’s tumor cells with a growing number of
approved therapies targeted to address specific sets of
cancer-causing DNA changes.
“The work currently underway at NYU Langone is ground-breaking
in the area of genomic sequencing and we are honored to be teaming
on the development efforts, including building an interface between
the new test and NYU Langone Health’s electronic medical records
system,” said Louis Culot, General Manager of Oncology Informatics
at Philips. “Philips Genomics Workspace, hosted on cloud-based
Philips HealthSuite, will help facilitate the integration into the
EMR so tests can be seamlessly ordered, reviewed, and shared by a
patient’s care team.”
“PACT reaffirms the goal behind its design, which was to provide
our patients with the best understanding of the genetic changes
driving their cancers,” said PACT designer Matija Snuderl, MD,
director of Molecular Pathology and Diagnostics in the Department
of Pathology at NYU Langone Health. “Knowing the genetics of their
tumor can help to determine which therapies will work for a given
patient and their eligibility for specific clinical trials. Beyond
the genetic changes that are important to the field now, we also
wanted PACT to detect the changes anticipated to be important in
diagnosis and treatment of cancer over the next five to ten
years.”
Philips end-to-end oncology solutions driving a clear
path to precision cancer careAccording to the National
Cancer Institute, patients today usually receive the same treatment
as others who have same type and stage of cancer, despite growing
evidence that they may respond differently [1]. Philips’ approach
to precision medicine is to arm care teams with expert clinical
guidance and a holistic view of the patient’s genotypic (the set of
genes in the DNA) and phenotypic (observable characteristics
influenced by environmental and lifestyle factors) information in
order to make decisions efficiently, collaboratively and
accurately. Recognizing the growing need for technological
advancement in oncology care – from early detection to diagnosis to
treatment to survivorship – Philips connects areas such as
pathology, genomics, molecular/multi-disciplinary tumor boards,
therapy decision making, molecular and imaging phenotyping, so
clinicians can have easy access to the insights they need to
provide high-quality personalized care.
With Philips Genomics Workspace, oncologists can map a patient’s
unique characteristics to a therapy that is best suited for
them and provide evidence on why that therapy is preferable.
Philips genomics solution combines individual institution genomic
knowledge bases and general industry knowledge bases, to help
molecular pathologists interpret genomic data and to provide
clinicians with ways to enable improved patient care. Visit Philips
Precision Medicine to learn more.
[1]
https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment.
For further information, please contact:
Kathy O’ReillyPhilips Global Press OfficeTel.: + 1
978-221-8919E-mail: kathy.oreilly@philips.comTwitter:
@kathyoreilly
Greg WilliamsResearch Communications DirectorNYU Grossman School
of MedicineTel: +1 212-404-3500E-mail:
Gregory.williams@nyulangone.org
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
well-being, and enabling better outcomes across the health
continuum – from healthy living and prevention, to diagnosis,
treatment and home care. Philips leverages advanced technology and
deep clinical and consumer insights to deliver integrated
solutions. Headquartered in the Netherlands, the company is a
leader in diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as in consumer health
and home care. Philips generated 2020 sales of EUR 17.3 billion and
employs approximately 77,000 employees with sales and services in
more than 100 countries. News about Philips can be found at
www.philips.com/newscenter.
- Physician using IntelliSpace Genomics
- IntelliSpace Genomics
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Sep 2023 to Sep 2024